People infected with HIV who control the infection without antiretroviral drug therapy have often served as foot soldiers for science, but now science owes them some answers. If the rare good fortune of being a so-called 'HIV controller' comes with a price—namely, immune activation that raises a person's risks of developing cardiovascular disease, diabetes and other health problems—might antiretroviral medications give these patients' overactive immune systems a much-needed break? Alla Katsnelson investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Guaraldi, G. et al. Clin. Infect. Dis. 53, 1120–1126 (2011).
Hunt, P.W. et al. J. Infect. Dis. 197, 126–133 (2008).
Hsue, P.Y. et al. AIDS 23, 1059–1067 (2009).
Pereyra, F. et al. AIDS 26, 2409–2412 (2012).
Hatano, H. et al. PLoS Pathog. 9, e1003691 (2013).
Chun, T.-W. et al. J. Infect. Dis. 208, 1443–1447 (2013).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Katsnelson, A. Control issues. Nat Med 20, 328–330 (2014). https://doi.org/10.1038/nm0414-328
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0414-328
